EE327 Belantamab Mafodotin, Pomalidomide, and Dexamethasone (BPd) in Relapsed/Refractory Multiple Myeloma (RRMM): Quality-Adjusted Life-Year (QALY) Results From a Cost-Effectiveness Model.
Saved in:
| Title: | EE327 Belantamab Mafodotin, Pomalidomide, and Dexamethasone (BPd) in Relapsed/Refractory Multiple Myeloma (RRMM): Quality-Adjusted Life-Year (QALY) Results From a Cost-Effectiveness Model. |
|---|---|
| Authors: | Suvannasankha, Attaya1 (AUTHOR), Kaiser, Martin2 (AUTHOR), Lee, Dawn3 (AUTHOR), Dlotko, Ewa4 (AUTHOR), Macleod, Paul4 (AUTHOR), Boytsov, Natalie5 (AUTHOR), Crossman-Morgan, Christina-Jane6 (AUTHOR), Jadhav, Vinay7 (AUTHOR), Kazeem, Gbenga8 (AUTHOR), Merchant, Adil6 (AUTHOR), Purser, Molly5 (AUTHOR), Riemer, Justin9 (AUTHOR), SAMYSHKIN, Yevgeniy6 (AUTHOR), McNamara, Simon8 (AUTHOR) |
| Source: | Value in Health. 2025 Supplement 1, Vol. 28 Issue 6, pS122-S122. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
